+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent



The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent



Laryngoscope 88(11): 1796-1824



The symptom complex of localized facial gustatory sweating and flushing during mastication (The Frey syndrome) is a common sequela of parotidectomy with facial nerve dissection. A thorough review of the literature concerning the Frey syndrome is reported. The procedure of tympanic neurectomy has received special emphasis with a review of 73 cases of tympanic neurectomy. The treatment modalities available, if tympanic neurectomy fails, are discussed. Important guidelines for the safe use of topical therapy to control gustatory sweating are presented as an alternative to surgical therapy. The author studied 129 post parotidectomy patients in whom 60% noted symptomatic gustatory sweating, and approximately one-fourth fo these symptomatic patients requested topical anticholinergic therapy, with one patient electing tympanic neurectomy. The only form of medical treatment presently available utilizes the topical application of scopolamine, a drug having potentially significant central nervous system side effects if systemically absorbed. In an effort to find an effective drug for topical application with a more favorable therapeutic index than scopolamine, glycopyrrolate was investigated. Glycopyrrolate was compared in varying concentrations to topical scopolamine in a personally conducted double blind clinical trial involving 16 patients. Initial results of this investigation suggest that topical glycopyrrolate in concentrations 0f 0.5% and 1.0% provide complete effective control of gustatory sweating for at least several days duration after a single application. There have been no significant side effects with the use of topical glycopyrrolate to date. Commercial topical antiperspirants were also investigated and found to be of limited benefit.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 041558672

Download citation: RISBibTeXText

PMID: 362094

DOI: 10.1288/00005537-197811000-00010


Related references

Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal): a double-blind evaluation of 15 patients. Laryngoscope 100(6): 651-653, 1990

Clinical evaluation of an anticholinergic in the irritable colon syndrome; a double blind study of tricyclamol. American Journal of Gastroenterology 31(1): 47-52, 1959

Double-blind crossover comparison between a beta-adrenergic agent and a new anticholinergic agent by metered dose inhaler. Respiration; International Review of Thoracic Diseases 36(1): 32-38, 1978

Clinical evaluation of tolnaftate. A double blind study of a topical antifungal agent. Dermatologica 133(6): 482-486, 1966

A double blind comparative evaluation of a new topical antibacterial agent mupirocin and placebo in the treatment of skin and soft tissue infections. Pharmatherapeutica 5(3): 198-204, 1988

Results of a double-blind clinical study of a new anticholinergic agent as an axillary antiperspirant. Illinois Medical Journal 131(3): 314-317, 1967

Comparative double-blind evaluation of a new topical antibacterial agent, mupirocin, compared with placebo in the treatment of skin and soft tissue infections. Pharmatherapeutica 5(3): 198-203, 1988

Topical anticholinergic drugs in the treatment of multiple hidrocystomas: a cross-over, randomized, double-blind, placebo-controlled study. Journal of the European Academy of Dermatology and Venereology, 2016

Combination of anticholinergic agent and H2 receptor antagonist in duodenal ulcer treatment--a randomized, double blind multicenter study. Indian Journal of Gastroenterology 12(3): 89-91, 1993

Evaluation of the effectiveness of and tolerance to a new psychopharmacological agent in the anxiety-depression syndrome (comparison in a double-blind study with diazepam). Giornale di Clinica Medica 58(9-10): 393-400, 1977

A tranqlizer-anticholinergic preparation in functional gastrointestinal disorders: a double-blind evaluation. California Medicine 111(2): 79-83, 1969

Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. British Journal of Dermatology 95(1): 83-88, 1976

Meclosorb, a new topical antibiotic agent in the treatment of acne vulgaris: a double-blind clinical study. Acta Dermato-Venereologica 64(4): 354-357, 1984

Efficacy of a newly developing topical agent for premature ejaculation Double blind clinical studies. Journal of Urology 157(4 SUPPL ): 182, 1997

A double-blind evaluation of topical capsaicin in pruritic psoriasis. Journal Of The American Academy Of Dermatology. 29(3): 438-442, 1993